ENGOT-EN9/LEAP-001: A phase III, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer
Date
2019Author
Marth, C.
Vulsteke, C.
Rubio, M. J.
Makker, V.
Braicu, E. I.
McNeish, I. A.
Radoslaw, M.
Ayhan, A.
Hasegawa, K.
Wu, X.
Dutta, L.
Xu, C.
Keefe, S. M.
Lee, J.
Pıgnata, S.